期刊文献+

结肠癌行根治术后辅助化疗的效果及影响预后的因素分析 被引量:4

下载PDF
导出
摘要 目的探讨行结肠癌根治术后辅助化疗的效果及影响预后的相关因素。方法将收治的结肠癌患者86例作为研究对象,根据患者行结肠癌根治术后是否辅助化疗分为研究组(辅助化疗)47例和对照组(单纯手术治疗)39例,观察两组临床疗效,分析影响预后的因素。结果两组治疗后癌症复发率、病灶转移率、1年内生存率和2年内生存率差异无统计学意义(P>0.05),3年后研究组生存率为76.60%,明显高于对照组的64.10%,差异有统计学意义(P<0.05);将生存时间<3年作为因变量,将临床分期Ⅲ期、CA19-9水平升高、肿瘤分化程度低、合并有其他疾病作为自变量进行多元Logistic回归分析,结果显示,上述各项条件均为降低预后的危险因素。结论行结肠癌根治术后予以辅助化疗能改善治疗效果,提高远期生存率,在临床上可根据临床分期选择合理的方案进行治疗。
作者 杨建新
机构地区 栾川县人民医院
出处 《现代诊断与治疗》 CAS 2019年第3期455-456,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献4

二级参考文献29

  • 1Muss HB, Bynum DL. Adjuvant chemotherapy in older patients with stage Ill colon cancer: an underused lifesaving treatment [J]. J Clin Oncol, 2012, 30 ( 21 ): 2576-2578. IX)h 10. 1200/ JCO. 2012.42. 3780.
  • 2Reese ES,Onukwugha E, Hanna N, et al. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients [J]. Cancer Med,2013,2(6) :907-915. IX)l: 10. 1002/cam4. 143.
  • 3Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes" B and C carcinoma of the colon- results from National Surgical Adjuvant Breast and Bowel Project C-04 [J]. J Clin Oncol, 1999,17(11) : 3553-3559.
  • 4Haller DG, Catalano PJ, Macdonald JS, et al. Phase IU study of fluorouracil, leucovorin, and levamisole in high-risk stage I][ and colon cancer: final report of Intergroup 0089 [J]. J Clin Oncol, 2005,23 (34) : 8671-8678. DOI: 10. 1200/JCO. 2004.00. 5686.
  • 5Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage [ or I]1 colon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009, 27 ( 19 ): 3109-3116. DOI: 10. 1200/ JCO. 2008.20. 6771.
  • 6Yothers G, O'Connell M J, Allegra C J, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses[J]. J Clin Onco[,2011, 29 ( 28 ): 3768-3774. IX)l: 10. 1200/ JCO. 2011.36.4539.
  • 7O'Connor ES, Greenblatt DY, Loconte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic {eatures[J]. J Clin Oncol,2011, 29 ( 25 )= 3381-3388. IX)l: 10.1200/ JCO. 2010.34. 3426.
  • 8Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer[J]. N Engl J Med, 2004, 350 ( 23 ): 2343-2351. DOI: 10. 1056/ NEJMoa032709.
  • 9KueblerJP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leueovorin as surgical adjuvant chemotherapy for stage ]] and HI colon cancer: results from NSABP C- 07[J]. J Clin Oncol,2007,25(16) :2198-2204. DOI: 10. 1200/JCO. 2006.08. 2974.
  • 10Campos FG, Calijuri-Hamra MC, Imperiale AR, et al. Locally advanced colorectal cancer: results of surgical treatment and prognostic factors[J]. Arq Gastroenterol, 2011,48(4) : 270-275.

共引文献66

同被引文献34

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部